Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Nenndorf – page 52

792 clinical trials in Bad Nenndorf, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Nenndorf at a glance
792
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

792 trials in Bad Nenndorf

Open in trial search

Asthma

Not recruiting

Study on the Effects of Dexpramipexole for Adolescents and Adults with Severe Eosinophilic Asthma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Areteia Therapeutics Inc.

Asthma

Not recruiting

Study on the Effectiveness and Safety of Budesonide, Glycopyrronium, and Formoterol Inhaler for Adults and Adolescents with Severe Asthma

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:AstraZeneca AB

Study on Durvalumab and Chemotherapy for Patients with Advanced Biliary Tract Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Finerenone
  • Sponsor:Bayer AG

Study on the Effectiveness and Safety of Dexamfetamine Sulfate for Adults with ADHD

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dexamfetamine Sulfate
  • Sponsor:MEDICE Arzneimittel Puetter GmbH & Co. KG

Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Giredestrant
  • Sponsor:F. Hoffmann-La Roche AG

Study on Chemotherapy with Paclitaxel, Cisplatin, and Carboplatin for Patients with Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Hepatic cirrhosis

Not recruiting

Study on the Safety of Zibotentan and Dapagliflozin for Patients with Liver Cirrhosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:AstraZeneca AB

Study on Axatilimab for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Syndax Pharmaceuticals Inc.

Hypertension

Not recruiting

Study on Baxdrostat for Lowering Blood Pressure in Patients with Resistant Hypertension

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Nenndorf

What the registry says about research in the country

01 Cardiovascular Diseases

Researchers in Bad Nenndorf are evaluating how a novel oral agent elecoglipron influences the progression of chronic kidney disease in adult participants, with all patients receiving background therapy with the SGLT2i dapagliflozin. The studies aim to reduce the risk of a sustained ≥50% decline in kidney function, end‑stage kidney disease, or death.

  • Renal outcomes linked to cardiovascular risk
  • Impact of SGLT2 inhibitor background therapy
  • Monitoring of eGFR decline and albuminuria levels
  • Composite endpoint of kidney failure and all‑cause mortality

Both trials are actively recruiting at two local sites, offering patients the opportunity to contribute to advancing therapies that bridge heart and kidney health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.